Short, cited digests of research and agency records, with a separate OfRoot perspective. Built for a clear first read and a direct path to the evidence.
FROM THE PRIMARY RECORDThe U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDThe U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDFDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDFDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDToday, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDThe U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDThe U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDThe U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
FROM THE PRIMARY RECORDFDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
OFROOT / WHO SHOULD REVIEW ITTeams monitoring the particular product, program, or topic named in this announcement; read its scope before assuming it applies to your work.
This collection shows the latest available primary-source digests in the current index. The Signal mark is labelled Brief when a checked primary-source digest is ready, or Sources when only a source reference is available. Digests are assembled automatically from approved records; they are not original reporting or full-paper reviews. How briefs are made →
MORE FROM OFROOT
A deeper look at the work behind the tools.
Explore OfRoot-authored guides on practical AI, connected systems, and the decisions behind useful software.